{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.288","value":"0.47"},{"groupId":"OG001","spread":"1.254","value":"0.89"},{"groupId":"OG002","spread":"0.599","value":"0.83"},{"groupId":"OG003","spread":"0.844","value":"0.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"title":"Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.607","value":"0.50"},{"groupId":"OG001","spread":"1.844","value":"-0.91"},{"groupId":"OG002","spread":"0.457","value":"0.66"},{"groupId":"OG003","spread":"1.648","value":"0.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"title":"Day 29"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.643","value":"1.02"},{"groupId":"OG001","spread":"1.873","value":"0.73"},{"groupId":"OG002","spread":"0.787","value":"1.00"},{"groupId":"OG003","spread":"1.167","value":"1.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"title":"Day 36"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.602","value":"0.53"},{"groupId":"OG001","spread":"1.682","value":"0.47"},{"groupId":"OG002","spread":"1.022","value":"1.09"},{"groupId":"OG003","spread":"1.22","value":"1.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"title":"Day 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.958","value":"0.78"},{"groupId":"OG001","spread":"0.907","value":"0.57"},{"groupId":"OG002","spread":"1.323","value":"0.86"},{"groupId":"OG003","spread":"0.704","value":"1.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"title":"Day 85"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.789","value":"0.33"},{"groupId":"OG001","spread":"1.141","value":"0.53"},{"groupId":"OG002","spread":"1.620","value":"0.96"},{"groupId":"OG003","spread":"1.024","value":"0.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"title":"Day 113"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.140","value":"0.13"},{"groupId":"OG001","spread":"1.500","value":"0.57"},{"groupId":"OG002","spread":"1.763","value":"0.33"},{"groupId":"OG003","spread":"2.392","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"title":"Day 169/Early Termination"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"description":"Summary of the change from baseline in hemoglobin (g/dL) by the pre-specified timepoints. Baseline was defined as the last measurement prior to dosing. Data were summarized for all treated participants who had at least 1 postdosing measurement.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo was administered within 28 days of screening. Subsequent doses were administered every 28 days for a total of four doses.","id":"OG000","title":"Placebo"},{"description":"0.1 mg/kg administered via subcutaneous injection every 28 days for a total of four doses (i.e., Days 1, 29, 57, and 85), with safety follow-up visits 1 week after each dose (i.e., Days 8, 36, 64, and 92). After completion of the treatment period, participants returned to the study site monthly for follow-up assessments for an additional 3 months (i.e., Days 113, 141, and 169).","id":"OG001","title":"0.1 mg/kg ACE 011"},{"description":"0.3 mg/kg administered via subcutaneous injection every 28 days for a total of four doses (i.e., Days 1, 29, 57, and 85), with safety follow-up visits 1 week after each dose (i.e., Days 8, 36, 64, and 92). After completion of the treatment period, participants returned to the study site monthly for follow-up assessments for an additional 3 months (i.e., Days 113, 141, and 169)","id":"OG002","title":"0.3 mg/kg ACE 011"},{"description":"0.5 mg/kg administered via subcutaneous injection every 28 days for a total of four doses (i.e., Days 1, 29, 57, and 85), with safety follow-up visits 1 week after each dose (i.e., Days 8, 36, 64, and 92). After completion of the treatment period, participants returned to the study site monthly for follow-up assessments for an additional 3 months (i.e., Days 113, 141, and 169).","id":"OG003","title":"0.5 mg/kg ACE 011"}],"paramType":"MEAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"Day 1 (baseline), Day 8, Day 29, Day 36, Day 57, Day 85, Day 113, Day 169","title":"Change From Baseline in Hemoglobin","type":"PRIMARY","unitOfMeasure":"g/dL"}